2X-121
As of the edition of 20 October 2026, 2X-121 is a small molecule: in active development; acts on PARP1, PARP2 and TNKS and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 6, 2 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Hormones; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 5 | 2 | 2 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eisai | Lead sponsor of trials | 2012 to now |
| Allarity Therapeutics | Lead sponsor of trials | 2018 to now |